About Vital Therapies (NASDAQ:VTL)
Vital Therapies, Inc. is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient's liver to regenerate to a healthy state, or to stabilize the patient until transplant. The ELAD System is a liver support system containing immortal human liver-derived cells, or VTL C3A cells. The Company initiated a Phase III clinical trial in severe acute alcoholic hepatitis (sAAH), referred to as VTL-308. Its VTL-308 is a randomized, open-label, multicenter, controlled, pivotal study, designed to evaluate the ELAD System in subjects with sAAH. It is based on pre-specified and post-hoc analyses of its VTI-208 phase III clinical trial in alcohol-induced liver decompensation (AILD). The Company's ELAD System consists of approximately four disposable ELAD C3A cell cartridges.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$1.47 per share
Price / Book3.57
Return on Equity-70.76%
Return on Assets-64.35%
Frequently Asked Questions for Vital Therapies (NASDAQ:VTL)
What is Vital Therapies' stock symbol?
Vital Therapies trades on the NASDAQ under the ticker symbol "VTL."
How were Vital Therapies' earnings last quarter?
Vital Therapies, Inc. (NASDAQ:VTL) released its quarterly earnings data on Wednesday, October, 25th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.32) by $0.02. During the same period in the prior year, the business earned ($0.32) EPS. View Vital Therapies' Earnings History.
Where is Vital Therapies' stock going? Where will Vital Therapies' stock price be in 2017?
3 equities research analysts have issued 12-month price targets for Vital Therapies' shares. Their predictions range from $6.00 to $10.00. On average, they anticipate Vital Therapies' share price to reach $8.00 in the next year. View Analyst Ratings for Vital Therapies.
Who are some of Vital Therapies' key competitors?
Some companies that are related to Vital Therapies include Aurinia Pharmaceuticals (AUPH), Atara Biotherapeutics (ATRA), GlycoMimetics (GLYC), Cytokinetics, Incorporated (CYTK), Mersana Therapeutics (MRSN), NantKwest (NK), Progenics Pharmaceuticals (PGNX), Corbus Pharmaceuticals Holdings (CRBP), NuCana PLC Sponsored ADR (NCNA), Seres Therapeutics (MCRB), Calithera Biosciences (CALA), Insys Therapeutics (INSY), CymaBay Therapeutics (CBAY), Stemline Therapeutics (STML), Mast Therapeutics (SVRA), MannKind Corporation (MNKD), ObsEva SA (OBSV) and AVEO Pharmaceuticals (AVEO).
Who are Vital Therapies' key executives?
Vital Therapies' management team includes the folowing people:
- Faheem Hasnain, Chairman of the Board (Age 58)
- Terence E. Winters Ph.D., Chief Executive Officer, Director (Age 74)
- Michael V. Swanson M.B.A., Chief Financial Officer (Age 55)
- Robert A. Ashley, Executive Vice President, Chief Technical Officer (Age 57)
- Duane D Nash M.D., Executive Vice President, Chief Business Officer (Age 46)
- Aron P. Stern M.B.A., Chief Administrative Officer (Age 61)
- Andrew Henry, Vice President - Clinical Operations (Age 50)
- Andrea Loewen-Rodriguez, Vice President - Regulatory Affairs and Quality Assurance (Age 47)
- Richard Murawski, Vice President - Manufacturing (Age 66)
- John Michael Dunn, General Counsel, Secretary (Age 63)
Who owns Vital Therapies stock?
Vital Therapies' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Victory Capital Management Inc. (6.17%), Granahan Investment Management Inc. MA (0.92%), Dowling & Yahnke LLC (0.12%), New York State Common Retirement Fund (0.10%), JPMorgan Chase & Co. (0.06%) and Dimensional Fund Advisors LP (0.05%). Company insiders that own Vital Therapies stock include Duane Nash, Faheem Hasnain, Jean Jacques Bienaime, John Michael Dunn, Muneer A Satter, Robert A Ashley and Terence E Winters. View Institutional Ownership Trends for Vital Therapies.
Who bought Vital Therapies stock? Who is buying Vital Therapies stock?
Vital Therapies' stock was acquired by a variety of institutional investors in the last quarter, including Granahan Investment Management Inc. MA, Dowling & Yahnke LLC, New York State Common Retirement Fund, JPMorgan Chase & Co., Victory Capital Management Inc. and Dimensional Fund Advisors LP. Company insiders that have bought Vital Therapies stock in the last two years include Duane Nash, Faheem Hasnain, Jean Jacques Bienaime, John Michael Dunn, Muneer A Satter, Robert A Ashley and Terence E Winters. View Insider Buying and Selling for Vital Therapies.
How do I buy Vital Therapies stock?
Shares of Vital Therapies can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vital Therapies' stock price today?
One share of Vital Therapies stock can currently be purchased for approximately $5.25.
How big of a company is Vital Therapies?
Vital Therapies has a market capitalization of $221.59 million. The company earns $-40,960,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis. Vital Therapies employs 87 workers across the globe.
How can I contact Vital Therapies?
Vital Therapies' mailing address is 15010 AVENUE OF SCIENCE SUITE 200, SAN DIEGO CA, 92128. The company can be reached via phone at 858-673-6840 or via email at [email protected]
MarketBeat Community Rating for Vital Therapies (VTL)MarketBeat's community ratings are surveys of what our community members think about Vital Therapies and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Vital Therapies (NASDAQ:VTL) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 1 Hold Rating, 2 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 2.67)|
|Consensus Price Target: ||$8.00 (52.38% upside)|
Consensus Price Target History for Vital Therapies (NASDAQ:VTL)
Analysts' Ratings History for Vital Therapies (NASDAQ:VTL)
(Data available from 11/24/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|5/18/2017||Raymond James Financial, Inc.||Initiated Coverage||Outperform -> Outperform||$6.00||High|
|3/10/2017||BTIG Research||Reiterated Rating||Hold||N/A|
|1/2/2017||Canaccord Genuity||Set Price Target||Buy||$10.00||N/A|
|3/14/2016||Credit Suisse Group||Reiterated Rating||Neutral||$9.00||N/A|
Earnings History and Estimates Chart for Vital Therapies (NASDAQ:VTL)
Earnings History by Quarter for Vital Therapies (NASDAQ VTL)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Vital Therapies (NASDAQ:VTL)
Current Year EPS Consensus Estimate: $-1.29 EPS
Next Year EPS Consensus Estimate: $-1.36 EPS
Dividend History for Vital Therapies (NASDAQ:VTL)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Vital Therapies (NASDAQ VTL)
Insider Ownership Percentage: 32.60%
Institutional Ownership Percentage: 25.44%
Insider Trades by Quarter for Vital Therapies (NASDAQ VTL)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/14/2017||Muneer A Satter||Director||Buy||130,000||$4.01||$521,300.00|| |
|9/13/2017||Jean Jacques Bienaime||Director||Buy||10,000||$4.00||$40,000.00|| |
|9/8/2017||Muneer A Satter||Director||Buy||50,000||$3.53||$176,500.00|| |
|6/14/2017||John Michael Dunn||General Counsel||Buy||2,500||$3.09||$7,725.00|| |
|6/14/2017||Muneer A Satter||Director||Buy||20,000||$3.07||$61,400.00|| |
|6/14/2017||Terence E Winters||Chairman||Buy||10,000||$3.10||$31,000.00|| |
|6/13/2017||Muneer A Satter||Director||Buy||10,000||$3.03||$30,300.00|| |
|6/12/2017||Muneer A Satter||Director||Buy||30,000||$3.11||$93,300.00|| |
|6/9/2017||Robert A Ashley||Insider||Buy||2,000||$3.18||$6,360.00|| |
|6/8/2017||Duane Nash||President||Buy||3,900||$3.12||$12,168.00|| |
|6/7/2017||Muneer A Satter||Director||Buy||20,000||$3.20||$64,000.00|| |
|6/6/2017||Muneer A Satter||Director||Buy||10,000||$3.19||$31,900.00|| |
|3/27/2017||Muneer A Satter||Director||Buy||3,750,000||$4.00||$15,000,000.00|| |
|8/12/2016||Faheem Hasnain||Director||Buy||118,243||$5.92||$699,998.56|| |
|10/28/2015||Muneer A Satter||Director||Buy||400,000||$5.50||$2,200,000.00|| |
|10/26/2015||Cheryl Cohen||Director||Buy||3,500||$7.17||$25,095.00|| |
|10/26/2015||John Michael Dunn||General Counsel||Buy||9,385||$6.81||$63,911.85|| |
|9/10/2015||Jean Jacques Bienaime||Director||Buy||14,000||$3.08||$43,120.00|| |
|10/10/2014||Terence E Winters||CEO||Buy||1,360||$14.86||$20,209.60|| |
|10/8/2014||Duane Nash||Insider||Buy||100||$17.50||$1,750.00|| |
|10/8/2014||Lowell Sears||Director||Buy||1,429||$17.50||$25,007.50|| |
|6/3/2014||Muneer A Satter||Director||Buy||14,500||$13.16||$190,820.00|| |
|4/23/2014||Muneer A Satter||Director||Buy||360,966||$12.00||$4,331,592.00|| |
Latest Headlines for Vital Therapies (NASDAQ VTL)
|Vital Therapies, Inc. (VTL) Given Average Recommendation of "Hold" by Analysts|
www.americanbankingnews.com - November 24 at 3:56 AM
|Analyzing Stemline Therapeutics (STML) and Vital Therapies (VTL)|
www.americanbankingnews.com - November 23 at 11:40 PM
|ValuEngine Downgrades Vital Therapies, Inc. (VTL) to Strong Sell|
www.americanbankingnews.com - November 18 at 12:04 AM
|Vital Therapies to Webcast Presentation at Upcoming Investor Conference|
feeds.benzinga.com - November 8 at 8:50 AM
|Financial Analysis: Vital Therapies (VTL) & Xenetic Biosciences (XBIO)|
www.americanbankingnews.com - November 7 at 1:28 AM
|-$0.30 Earnings Per Share Expected for Vital Therapies, Inc. (VTL) This Quarter|
www.americanbankingnews.com - November 6 at 3:22 AM
|Vital Therapies (VTL) versus Its Rivals Head-To-Head Contrast|
www.americanbankingnews.com - October 31 at 3:06 PM
|Vital Therapies, Inc. (VTL) Downgraded to Sell at Zacks Investment Research|
www.americanbankingnews.com - October 31 at 11:53 AM
|Vital Therapies, Inc. (VTL) Given Average Recommendation of "Hold" by Brokerages|
www.americanbankingnews.com - October 30 at 1:22 AM
|Edited Transcript of VTL earnings conference call or presentation 25-Oct-17 8:30pm GMT|
finance.yahoo.com - October 28 at 8:34 AM
|Vital Therapies, Inc. (VTL) Announces Earnings Results|
www.americanbankingnews.com - October 26 at 9:06 PM
|Vital Therapies, Inc. (VTL) Set to Announce Earnings on Wednesday|
www.americanbankingnews.com - October 25 at 8:36 AM
|ValuEngine Upgrades Vital Therapies, Inc. (VTL) to "Sell"|
www.americanbankingnews.com - October 21 at 9:52 AM
| Analysts Anticipate Vital Therapies, Inc. (VTL) Will Post Earnings of -$0.30 Per Share|
www.americanbankingnews.com - October 17 at 12:52 PM
|BidaskClub Upgrades Vital Therapies, Inc. (VTL) to Strong-Buy|
www.americanbankingnews.com - October 5 at 11:20 PM
|Vital Therapies, Inc. (VTL) Receives Consensus Rating of "Hold" from Brokerages|
www.americanbankingnews.com - October 5 at 10:20 PM
|Vital Therapies, Inc. (VTL) Stock Rating Lowered by Zacks Investment Research|
www.americanbankingnews.com - October 5 at 6:58 PM
|Reviewing Vital Therapies (VTL) and The Competition|
www.americanbankingnews.com - October 5 at 12:16 AM
|All You Need To Know About Vital Therapies Inc’s (VTL) Risks|
finance.yahoo.com - October 3 at 2:44 PM
|Is It Too Late To Buy Vital Therapies Inc (VTL)?|
finance.yahoo.com - September 16 at 10:17 AM
|Insider Buying: Vital Therapies, Inc. (VTL) Director Buys 10,000 Shares of Stock|
www.americanbankingnews.com - September 14 at 11:56 PM
|Vital Therapies, Inc. (VTL) Director Muneer A. Satter Purchases 130,000 Shares|
www.americanbankingnews.com - September 14 at 10:52 PM
|Vital Therapies, Inc. (VTL) Director Buys $176,500.00 in Stock|
www.americanbankingnews.com - September 12 at 7:54 PM
|Vital Therapies Announces Recent and Upcoming Scientific Presentations and Participation in Upcoming Investor Conference|
finance.yahoo.com - September 11 at 8:25 AM
|Vital Therapies Appoints Former Receptos President and CEO Faheem Hasnain as Chairman of the Board of Directors|
feeds.benzinga.com - September 6 at 8:23 AM
|Edited Transcript of VTL earnings conference call or presentation 3-Aug-17 8:30pm GMT|
finance.yahoo.com - August 5 at 8:24 AM
|Vital Therapies Announces Second Quarter 2017 Financial Results|
finance.yahoo.com - August 4 at 9:53 AM
|Vital Therapies, Inc. (NASDAQ:VTL) Issues Quarterly Earnings Results|
www.americanbankingnews.com - August 4 at 12:50 AM
|Vital Therapies, Inc. (VTL) Set to Announce Earnings on Monday|
www.americanbankingnews.com - July 24 at 8:43 AM
|Vital Therapies, Inc. (VTL) Expected to Post Earnings of -$0.30 Per Share|
www.americanbankingnews.com - July 13 at 12:22 AM
|Vital Therapies reports 1Q loss|
marketbeat.com - May 9 at 7:28 PM
|VITAL THERAPIES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statement|
biz.yahoo.com - March 23 at 8:57 PM
|VITAL THERAPIES INC Files SEC form 8-K, Other Events|
biz.yahoo.com - March 21 at 8:21 PM
|Vital Therapies Announces Fourth Quarter and Full Year 2016 Financial Results|
us.rd.yahoo.com - March 8 at 12:24 AM
|4:02 pm Vital Therapies misses by $0.01|
us.rd.yahoo.com - March 8 at 12:24 AM
|Q4 2016 Vital Therapies Inc Earnings Release - After Market Close|
biz.yahoo.com - March 7 at 8:19 AM
|Q3 2016 Vital Therapies Inc Earnings Release - After Market Close|
biz.yahoo.com - November 3 at 12:39 PM
|Vital Therapies (VTL) Offers Corporate Update; Says 14 Subjects Enrolled in VTL-308|
www.streetinsider.com - September 15 at 8:09 PM
|VITAL THERAPIES INC Files SEC form 8-K, Entry into a Material Definitive Agreement|
biz.yahoo.com - August 29 at 8:05 PM
|VITAL THERAPIES INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits|
biz.yahoo.com - August 15 at 10:14 AM
|Vital Therapies Announces Second Quarter Financial Results|
www.nasdaq.com - August 2 at 8:37 PM
|Q2 2016 Vital Therapies Inc Earnings Release - After Market Close|
biz.yahoo.com - August 2 at 7:22 AM
|VITAL THERAPIES INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of|
biz.yahoo.com - May 27 at 4:33 PM
|VITAL THERAPIES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhib|
biz.yahoo.com - May 9 at 5:13 PM
|Q1 2016 Vital Therapies Inc Earnings Release - After Market Close|
biz.yahoo.com - May 9 at 7:07 AM
Vital Therapies (NASDAQ VTL) Chart for Friday, November, 24, 2017